CRISPR Therapeutics AG - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CRISPR Therapeutics AG on May 23, 2024. The filing discloses the appointment of a new Chief Operating Officer and the terms of the associated employment agreement.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes
The primary material change reported is the promotion of Julianne Bruno to Chief Operating Officer, effective May 23, 2024. Prior to this appointment, Ms. Bruno served as Senior Vice President and Head of Programs & Portfolio Management since March 2023.
Employment Agreement and Compensation Terms
- Base Salary: $460,000 annually.
- Annual Bonus: Target of 45% of base salary (pro-rated for 2024).
- Equity Grant: One-time grant of 20,000 restricted stock units (RSUs).
- Vesting Schedule: 25% of RSUs vest on each of the first four anniversaries of the grant date, contingent on continued service.
- Termination Provisions:
- Standard termination without Cause or resignation for Good Reason requires a six-month notice period during which compensation and equity vesting continue.
- During the notice period, the executive may be placed on administrative leave and engage in outside consulting or employment.
- Termination within 12 months of a Change in Control triggers a 12-month notice period and full acceleration of all equity awards.
Investor Verification Checklist
- Verify the full text of the Employment Agreement filed as Exhibit 10.1 for complete definitions of "Cause," "Good Reason," and "Change in Control."
- Confirm the impact of the 20,000 RSU grant on total share count and potential dilution.
- Review the company's most recent 10-Q or 10-K for current cash position to assess the ability to fund the new executive compensation package.
- Monitor future filings for any changes to the vesting schedule or additional equity grants.